Nextera MeDip !!! hell yeah
this sounds like the best option for me??? Did you try it out I would like to try it as well (I'm a big Nextera fan)!!! I read somewhere else that Illumina primers can be methylated sometimes, but what about the transposon insert from the Nextera? If the nextera transposon adapters have a methylated site that would certainly would be a problem.
Unconfigured Ad
Collapse
X
-
Has anyone tried using MethylMiner to enrich DNA that has been tagged and fragmented by Nextera? I would like to try this protocol, but it would be nice to hear others input before potentially wasting the time and money.
For example: Nextera tagmentation --> MethylMiner --> TruSeq/Nextera probe hybridization enrichment --> Sequencing of native DNA and methylated DNA fractions.
Leave a comment:
-
-
The main difference between MeDIP and ChIP is that after the IP, MeDIP DNA is single-stranded, whereas ChIP DNA is double-stranded.
You have a few options (off the top of my head):
a) add the Illumina adaptors before you do the MeDIP
b) regenerate the second strand of the MeDIP product before putting on the Illumina adaptors
c) some other tricky stuff
So to avoid all these problems we decided to use MethylMiner from Invitrogen, which keeps the DNA double-stranded.
Leave a comment:
-
-
We've done quite a bit of MeDIP and related types of study. The MeDIP libraries get treated much like any other ChIP library. Their composition is slightly biased but not to a level where it causes problems with library generation or sequencing.
The main issue we've seen has been duplicated libraries resulting from over-amplification of the ChIPped material. In many cases this was because we were looking at libraries for samples with virtually no methylation, so very little material came out of the ChIP. Once the libraries have been prepared and quantitated we've had very good yields out of them though. If you're having a problem and other types of library are working OK then I'd suspect the ChIP protocols first.
You can see the protocols used on our site in one of our recent publications (the supplementary info will contain much more useful information). If you have specific questions I can ask the people who actually do the sample prep.
Leave a comment:
-
-
HEllo,
I am also interested in doing MeDIP-seq. Do you have a working protocol where I can try out.
Leave a comment:
-
-
MeDIP-Seq (Illumina/Solexa)
Dear All,
Does anyone of you have experience with MeDIP-seq? We are currently trying to do this sequencing using Illumina/ Solexa technology, but we couldn´t get enough reads.
Normally we get around 15 million reads, but for our sample the maximum that we could get is 700 000.
Do we need some special parameters during the cluster generations for the MeDIP sample? for example adding betain or increasing the T° of the denaturation before the first sequencing cycle?
I will be very grateful if someone share his experience with us.
Thanks in advance
RegardsTags: None
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Yesterday, 12:17 PM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 12:17 PM
|
||
|
Started by SEQadmin2, 07-23-2026, 11:41 AM
|
0 responses
11 views
0 reactions
|
Last Post
by SEQadmin2
07-23-2026, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
37 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
Leave a comment: